NCT05506943Phase 2, phase 3Active not recruiting

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

Study sponsor: Compass Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-08-31Estimated
Enrollment · participants168Actual
Source updated2026-11-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Best Overall Response Description: Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR) as assessed by RECIST 1.1 Time frame: From randomization to treatment discontinuation for any reason, average 6 months. After: Measure: Best Overall Response Description: Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions. Time frame: From randomization to treatment discontinuation for any reason, average 6 months.

Check registry source

· 1 field changed

Primary completion date changed

Before: 1 Dec 2026. After: 31 Aug 2027.

Check registry source

· 3 fields changed

Completion date type changed

Before: Actual. After: Estimated.

Primary completion date changed

Before: 21 Jan 2026. After: 1 Dec 2026.

Recruitment status changed

Before: Completed. After: Active not recruiting.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 150 participants (planned). After: 168 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jul 2025. After: 21 Jan 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview